An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Epinephrine (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Sponsors ARS Pharmaceuticals
Most Recent Events
- 15 Apr 2025 Status changed from planning to not yet recruiting.
- 20 Mar 2025 According to an ARS Pharmaceuticals media release, company plans to initiate a Phase 2b clinical trial in the second quarter of 2025 and the trial is expected to enroll patients in the U.S. and Europe, with topline data anticipated in early 2026.
- 13 Nov 2024 According to an ARS Pharmaceuticals media release, the Phase 2b trial is expected to begin in early 2025, followed by a potential single pivotal efficacy trial.